Search
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] This drug was approved by the FDA on April 26, 2022.[L41645]
Isosorbide mononitrate
go.drugbank.com/drugs/DB01020ApprovedInvestigational[T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of
Mycophenolate mofetil
go.drugbank.com/drugs/DB00688ApprovedInvestigational[L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995.
Ivosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] Ensartinib was approved by the FDA for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously
Metamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnApprovals of the NDA's for metamizole drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977, 42 FR 30893).
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedP188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217].
Peginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigationalIt was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.
Geraniol
go.drugbank.com/drugs/DB14183Approvedpharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration (FDA
Ceritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalThe FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.